PMID- 23993653
OWN - NLM
STAT- MEDLINE
DCOM- 20131125
LR  - 20131007
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Linking)
VI  - 263
IP  - 1-2
DP  - 2013 Oct 15
TI  - Transplantation of Schwann cells co-cultured with brain-derived neurotrophic 
      factor for the treatment of experimental autoimmune neuritis.
PG  - 83-90
LID - S0165-5728(13)00213-0 [pii]
LID - 10.1016/j.jneuroim.2013.08.004 [doi]
AB  - The aim of this study was to investigate the effects of transplantation of 
      Schwann cells (SCs) co-cultured with brain-derived neurotrophic factor (BDNF) for 
      the treatment of experimental autoimmune neuritis (EAN). Primary SCs were 
      co-cultured with various BDNF concentrations, and the optimum concentration was 
      determined by cell proliferation, and NGF and FGF levels. A rat model of EAN was 
      established by immunization with 400mug of P2 peptide dissolved in Freund's 
      complete adjuvant. SCs were labeled with CFSE and injected into the cisterna 
      magna 14days after immunization. We found proliferation of SCs, and NGF and FGF 
      levels were highest at a BDNF concentration of 50ng/mL. Compared with EAN group, 
      SCs+BDNF group showed the lower paralysis scores from day 34 to day 45, and in 
      sciatic nerves showed a significant decrease in inflammatory cell infiltration 
      (involved CD4-, CD8- and CD68-positive cells) at days 25 and 35, an alleviated 
      demyelination at days 35 and 45, and an increase in S-100-positive cells and a 
      decrease in NGF-positive cells at each time point (P<0.05). Compared with the EAN 
      group, the SCs+BDNF group showed, in sciatic nerves, the mRNA level of NGF was 
      significantly decreased but that of S-100 was increased at day 25, the mRNA level 
      of CCL3 was also remarkably reduced at day 35, and the mRNA level of CD11a, CCL3 
      and NGF was reduced but that of S-100 was elevated at day 45 (P<0.05). There were 
      no differences in results between the SCs group and EAN group. In the end, we 
      draw the conclusions that the exogenous SCs injected through cisterna magna can 
      migrate to the injured peripheral nerves, BDNF promotes the proliferation and 
      secretory function of SCs in vitro, and BDNF-treated SCs in vivo can reduce 
      paralysis, inflammation, and demyelination and improve the self-repair capability 
      of body in EAN.
CI  - (c) 2013.
FAU - Hou, Xiaojun
AU  - Hou X
AD  - Department of Neurology, the Second Affiliated Hospital of Harbin Medical 
      University, Heilongjiang 150086, China.
FAU - Liang, Qingcheng
AU  - Liang Q
FAU - Wu, Yun
AU  - Wu Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130815
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Brain-Derived Neurotrophic Factor/*therapeutic use
MH  - Cell Movement/immunology
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Male
MH  - Neuritis, Autoimmune, Experimental/*immunology/surgery/*therapy
MH  - Random Allocation
MH  - Rats
MH  - Rats, Inbred Lew
MH  - Rats, Sprague-Dawley
MH  - Schwann Cells/physiology/*transplantation
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Brain derived neurotrophic factor (BDNF)
OT  - Experimental autoimmune neuritis (EAN)
OT  - Schwann cells (SCs)
OT  - Sciatic nerve
EDAT- 2013/09/03 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/09/03 06:00
PHST- 2013/04/20 00:00 [received]
PHST- 2013/08/03 00:00 [revised]
PHST- 2013/08/06 00:00 [accepted]
PHST- 2013/09/03 06:00 [entrez]
PHST- 2013/09/03 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S0165-5728(13)00213-0 [pii]
AID - 10.1016/j.jneuroim.2013.08.004 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2013 Oct 15;263(1-2):83-90. doi: 10.1016/j.jneuroim.2013.08.004. 
      Epub 2013 Aug 15.